Switch to:
More From Other Websites
Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two... Dec 04 2016
IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and... Dec 03 2016
[$$] New Tax Rules on Corporate Inversions Face Uncertain Future Dec 03 2016
[$$] Tax Rules on Corporate Inversions Face Uncertain Future Dec 02 2016
Uterine Fibroids Segment May Offer Opportunity for NBIX Dec 02 2016
AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy Dec 02 2016
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix Dec 02 2016
Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta? Dec 02 2016
Billionaire Larry Robbins Confidently Piles Into CBS, Anthem, As Merger Battles Continue Dec 02 2016
Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016
What Do Analysts Recommend for Gilead Sciences Stock? Dec 02 2016
FDA Orphan Drug Designation for AbbVie's Risankizumab Dec 01 2016
OraSure Stock Sets Up For Buy Point On Hep C Contract, Helix Win Dec 01 2016
Is AbbVie Inc (ABBV) A Good Stock To Buy? Dec 01 2016
AbbVie’s ABT-494 May Become Standard of Care in Immunology Dec 01 2016
ETFs with exposure to AbbVie, Inc. : December 1, 2016 Dec 01 2016
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S. Dec 01 2016
Can AbbVie’s Anti-Tau Therapeutics Help Late-Stage Alzheimer’s Patients? Dec 01 2016
AbbVie’s Plans for ABT-555, a Novel Multiple Sclerosis Therapy Dec 01 2016
Why AbbVie Wants to Develop Anti-Tau Therapies Dec 01 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK